Pharmanutra マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Roberto Lacorte

最高経営責任者

€1.9m

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	0.1%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	less than a year

経営陣の近況

Recent updates

CEO（最高経営責任者

Roberto Lacorte (55 yo)

no data

在職期間

€1,918,290

報酬

Mr. Roberto Lacorte serves as Vice Chairman, Managing Director and Vice President of Pharmanutra S.p.A. Between January 1995 and April 1996, Mr. Lacorte carried out military service with the Marines. Betwe...

取締役

名称	ポジション	在職期間	報酬	所有権
Andrea Lacorte	Chairman & President	no data	€2.19m	データなし
Roberto Lacorte	Vice Chairman	no data	€1.92m	0.15% € 762.2k
Carlo Volpi	Delegate Advisor	no data	€1.77m	10.56% € 55.1m
Germano Tarantino	Scientific Director & Executive Director	12.7yrs	€586.16k	データなし
Marida Zaffaroni	Independent Director	no data	€41.00k	データなし
Alessandro Calzolari	Lead Independent Director	no data	€41.00k	データなし
Giovanna Zanotti	Independent Director	no data	€41.00k	データなし
Debora Mazzacherini	Standing Auditor	no data	データなし	データなし
Michele Giordano	President of Supervisory Board	less than a year	データなし	データなし
Pasquale Giovinazzo	Internal Member of Supervisory Board	less than a year	データなし	データなし

0.7yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: PHNMの取締役会は経験豊富ではない ( 0.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Pharmanutra マネジメント

マネジメント基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Less than half of directors are independent

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Less than half of directors are independent

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

Pharmanutra マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Less than half of directors are independent

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Less than half of directors are independent

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14